RECRUITING

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Conditions

Gastrostomy Gastric GastroEsophageal Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Official Title

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Quick Facts

Study Start:2022-05-11

Study Completion:2026-05-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05205343

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Able to speak and read English or Spanish (for patients enrolled at MD Anderson and Mayo Clinic), English or Korean (for patients enrolled at Yonsei), and English or Japanese (for patients enrolled at Keio) 2. Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention 3. Age ≥ 18	1. Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract 2. Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent 3. Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion 4. Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Inclusion Criteria

Exclusion Criteria

1. Able to speak and read English or Spanish (for patients enrolled at MD Anderson and Mayo Clinic), English or Korean (for patients enrolled at Yonsei), and English or Japanese (for patients enrolled at Keio)
2. Patients with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention
3. Age ≥ 18

1. Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract
2. Patients with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent
3. Subjects deemed unable to comply with study and/or follow-up procedures, at investigators' discretion
4. Patients who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)

Contacts and Locations

Study Contact

Naruhiko Ikoma, MD

CONTACT

(832) 729-2675

nikoma@mdanderson.org

Principal Investigator

Naruhiko Ikoma, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

M D Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Naruhiko Ikoma, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-11

Study Completion Date2026-05-31

Study Record Updates

Study Start Date2022-05-11

Study Completion Date2026-05-31

Terms related to this study

Additional Relevant MeSH Terms

Gastrostomy
Gastric
GastroEsophageal Cancer